CLS vs. CPH.TO

Last updated Jun 9, 2026

CLS (Celestica Inc.) and CPH.TO (Cipher Pharmaceuticals Inc.) are both stocks. CLS operates in Electronic Components (Technology), while CPH.TO operates in Drug Manufacturers - Specialty & Generic (Healthcare). Over the past 10 years, CLS returned 43.16%/yr vs 7.91%/yr for CPH.TO. At a 0.12 correlation, their price movements are largely independent.

Performance

CLS vs. CPH.TO - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Celestica Inc. (CLS) and Cipher Pharmaceuticals Inc. (CPH.TO). The values are adjusted to include any dividend payments, if applicable.

Different Trading Currencies

CLS is traded in USD, while CPH.TO is traded in CAD. To make them comparable, the CPH.TO values have been converted to USD using the latest available exchange rates.

Returns By Period

In the year-to-date period, CLS achieves a 30.75% return, which is significantly higher than CPH.TO's 10.08% return. Over the past 10 years, CLS has outperformed CPH.TO with an annualized return of 43.16%, while CPH.TO has yielded a comparatively lower 7.91% annualized return.

CLS

• 1D: 3.98%
• 1M: 2.92%
• YTD: 30.75%
• 6M: 13.42%
• 1Y: 220.14%
• 3Y*: 209.55%
• 5Y*: 114.81%
• 10Y*: 43.16%

CPH.TO

• 1D: -0.04%
• 1M: -16.23%
• YTD: 10.08%
• 6M: 14.24%
• 1Y: 24.86%
• 3Y*: 62.35%
• 5Y*: 56.53%
• 10Y*: 7.91%

*Multi-year figures are annualized to reflect compound growth (CAGR)

CLS vs. CPH.TO - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
CLS Celestica Inc.	30.75%	220.27%	215.23%	159.80%	1.26%	37.92%	-2.42%	-5.70%	-16.32%	-11.56%
CPH.TO Cipher Pharmaceuticals Inc.	10.08%	10.20%	138.31%	47.79%	104.02%	90.42%	-36.49%	-8.51%	-67.81%	7.26%

Correlation

The correlation between CLS and CPH.TO is 0.08, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.08
Correlation (3Y) Calculated over the trailing 3-year period	0.14
Correlation (5Y) Calculated over the trailing 5-year period	0.11
Correlation (10Y) Calculated over the trailing 10-year period	0.11
Correlation (All Time) Calculated using the full available price history since Jul 5, 2006	0.12

Fundamentals

Market Cap CLS : $44.72B CPH.TO : CA$435.58M
EPS CLS : $8.28 CPH.TO : CA$1.19
PE Ratio CLS : 46.65 CPH.TO : 14.22
PEG Ratio CLS : 0.63 CPH.TO : 0.17
PS Ratio CLS : 3.24 CPH.TO : 8.65
PB Ratio CLS : 21.31 CPH.TO : 3.28
Total Revenue (TTM) CLS : $13.81B CPH.TO : CA$50.92M
Gross Profit (TTM) CLS : $1.60B CPH.TO : CA$37.95M
EBITDA (TTM) CLS : $1.32B CPH.TO : CA$25.12M

Return for Risk

CLS vs. CPH.TO — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

CLS

CLS Risk / Return Rank: 93
CLS Sharpe Ratio Rank: 95
CLS Sortino Ratio Rank: 89
CLS Omega Ratio Rank: 88
CLS Calmar Ratio Rank: 96
CLS Martin Ratio Rank: 95

CPH.TO

CPH.TO Risk / Return Rank: 64
CPH.TO Sharpe Ratio Rank: 64
CPH.TO Sortino Ratio Rank: 65
CPH.TO Omega Ratio Rank: 61
CPH.TO Calmar Ratio Rank: 66
CPH.TO Martin Ratio Rank: 65

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

CLS vs. CPH.TO - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Celestica Inc. (CLS) and Cipher Pharmaceuticals Inc. (CPH.TO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	CLS	CPH.TO	Difference
Sharpe ratio: Return per unit of total volatility	3.06	0.59	+2.47
Sortino ratio: Return per unit of downside risk	2.94	1.31	+1.63
Omega ratio: Gain probability vs. loss probability	1.39	1.15	+0.24
Calmar ratio: Return relative to maximum drawdown	7.58	1.03	+6.55
Martin ratio: Return relative to average drawdown	18.88	2.22	+16.66
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

CLS vs. CPH.TO - Sharpe Ratio Comparison

The current CLS Sharpe Ratio is 3.06, which is higher than the CPH.TO Sharpe Ratio of 0.59. The chart below compares the historical Sharpe Ratios of CLS and CPH.TO, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Sharpe Ratios by Period

	CLS	CPH.TO	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	3.06	0.59	+2.47
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	2.01	1.14	+0.87
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	0.87	0.13	+0.74
Sharpe Ratio (All Time) Calculated using the full available price history	0.27	0.07	+0.20

Drawdowns

CLS vs. CPH.TO - Drawdown Comparison

The maximum CLS drawdown since its inception was -96.93%, roughly equal to the maximum CPH.TO drawdown of -98.29%. Use the drawdown chart below to compare losses from any high point for CLS and CPH.TO.

Drawdown Indicators

	CLS	CPH.TO	Difference
Max Drawdown Largest peak-to-trough decline	-96.93%	-98.29%	+1.36%
Max Drawdown (1Y) Largest decline over 1 year	-29.24%	-24.22%	-5.02%
Max Drawdown (3Y) Largest decline over 3 years	-53.96%	-46.02%	-7.94%
Max Drawdown (5Y) Largest decline over 5 years	-53.96%	-46.02%	-7.94%
Max Drawdown (10Y) Largest decline over 10 years	-80.60%	-95.16%	+14.56%
Current Drawdown Current decline from peak	-18.18%	-24.23%	+6.05%
Average Drawdown Average peak-to-trough decline	-73.36%	-65.74%	-7.62%
Ulcer Index Depth and duration of drawdowns from previous peaks	11.72%	11.22%	+0.50%

Volatility

CLS vs. CPH.TO - Volatility Comparison

Celestica Inc. (CLS) has a higher volatility of 26.60% compared to Cipher Pharmaceuticals Inc. (CPH.TO) at 13.93%. This indicates that CLS's price experiences larger fluctuations and is considered to be riskier than CPH.TO based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	CLS	CPH.TO	Difference
Volatility (1M) Calculated over the trailing 1-month period	26.60%	13.93%	+12.67%
Volatility (6M) Calculated over the trailing 6-month period	55.08%	28.17%	+26.91%
Volatility (1Y) Calculated over the trailing 1-year period	72.52%	42.14%	+30.38%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	57.62%	49.98%	+7.64%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	49.93%	61.43%	-11.50%

Dividends

CLS vs. CPH.TO - Dividend Comparison

Neither CLS nor CPH.TO has paid dividends to shareholders.

Tickers have no history of dividend payments

Financials

CLS vs. CPH.TO - Profitability Comparison

The chart below illustrates the profitability comparison between Celestica Inc. and Cipher Pharmaceuticals Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

CLS - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Celestica Inc. reported a gross profit of 437.20M and revenue of 4.05B. Therefore, the gross margin over that period was 10.8%.

CPH.TO - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Cipher Pharmaceuticals Inc. reported a gross profit of 8.35M and revenue of 12.30M. Therefore, the gross margin over that period was 67.9%.

CLS - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Celestica Inc. reported an operating income of 272.10M and revenue of 4.05B, resulting in an operating margin of 6.7%.

CPH.TO - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Cipher Pharmaceuticals Inc. reported an operating income of 5.50M and revenue of 12.30M, resulting in an operating margin of 44.7%.

CLS - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Celestica Inc. reported a net income of 212.30M and revenue of 4.05B, resulting in a net margin of 5.3%.

CPH.TO - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Cipher Pharmaceuticals Inc. reported a net income of 6.06M and revenue of 12.30M, resulting in a net margin of 49.3%.

Frequently Asked Questions

Can I hold both CLS and CPH.TO in my portfolio?

CLS and CPH.TO have a correlation of 0.08, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.